Rabishield 100IU Injection

Rabishield 100IU injections contain active components known as Rabies monoclonal human antibodies. One of the significant advantages is that it offers immediate passive protection against Rabies virus. This is particularly important when exposure is high-risk and waiting for the body to produce its antibodies after vaccination might require a faster pace. It is particularly beneficial for people with weak or compromised immune systems, like those who have HIV/AIDS or who are undergoing immunosuppressive therapies. Neutralizing the virus at the point of exposure significantly decreases the chance of contracting rabies, mainly when administered quickly after an event of high risk, such as an injury from a vicious animal. Many people hesitate to take on the entire course of rabies vaccines due to the required doses or the discomfort resulting from injections. This can improve compliance since they offer immediate protection and could reduce the fear of exposure to rabies.
Rabishield 100IU injections may be unsuitable if someone suffers from a known hypersensitivity or a severe allergic reaction to any of its constituents. It should not be used for exposure with low risk and minimal chance of rabies transmission. The use of it during breastfeeding and pregnancy could be a contraindication due to the lack of research evidence, and the potential risks and benefits must be carefully assessed. It is also possible to use for older patients when indicated. When indicated, Rabishield 100IU injection can be administered to children as a part of rabies post-exposure prophylaxis.